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Background: Obesity is prevalent among adolescents and is associated with serious 
health consequences. Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) 
are bariatric procedures that cause significant weight loss in adults and are increasingly 
being performed in adolescents with morbid obesity. Data comparing outcomes of 
RYGB vs. SG in this age-group are scarce. This study aims to compare short-term 
(1–6 months) and longer-term (7–18 months) body mass index (BMI) and biochemical 
outcomes following RYGB and SG in adolescents/young adults.
Methods: A retrospective study using data extracted from medical records of patients 
16–21 years who underwent RYGB or SG between 2012 and 2014 at a tertiary care 
academic medical center.
results: Forty-six patients were included in this study: 24 underwent RYGB and 22 
underwent SG. Groups did not differ for baseline age, sex, race, or BMI. BMI reductions 
were significant at 1–6 months and 7–18 months within groups (p < 0.0001), but did 
not differ by surgery type (p = 0.65 and 0.09, for 1–6 months and 7–18 months, respec-
tively). Over 7–18 months, within-group improvement in low-density lipoprotein (LDL) 
(−24 ± 6 in RYGB, p = 0.003, vs. −7 ± 9 mg/dl in SG, p = 0.50) and non-high-density 
lipoprotein (non-HDL) cholesterol (−23 ±  8 in RYGB, p =  0.02, vs. −12 ±  7 in SG, 
p = 0.18) appeared to be of greater magnitude following RYGB. However, differences 
between groups did not reach statistical significance. When divided by non-alcoholic 
steatohepatitis stages (NASH), patients with Stage II–III NASH had greater reductions in 
alanine aminotransferase levels vs. those with Stage 0–I NASH (−45 ± 18 vs. −9 ± 3, 
p = 0.01) after 7–18 months. RYGB and SG groups did not differ for the magnitude of 
post-surgical changes in liver enzymes.
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conclusion: RYGB and SG did not differ for the magnitude of BMI reduction across 
groups, though changes trended higher following RYGB. Further prospective studies are 
needed to confirm these findings.
Keywords: bariatric surgery, adolescence, roux-en-Y gastric bypass, sleeve gastrectomy, obesity
inTrODUcTiOn
Obesity is a major global challenge, which affects children, 
adolescents, and adults. In the United States, between 2009 
and 2010, 31.8% of children aged 2–19 years were classified as 
overweight and 16.9% as obese (1). Of concern, most children 
and adolescents with obesity remain obese as adults (2). Obesity 
causes co-morbidities, such as insulin resistance and type 2 
diabetes mellitus (T2D), cardiovascular disease, hyperlipidemia, 
hypertension, obstructive sleep apnea, non-alcoholic fatty liver 
disease, polycystic ovary syndrome, and degenerative joint 
disease (3–5). In addition, obesity is associated with psychiatric 
conditions, such as depression and eating disorders, and with 
significant psychosocial stresses, including bullying, isolation, 
and discrimination. Therefore, reduced quality of life and life 
expectancy are important consequences of obesity and its related 
co-morbidities (6).
In this context, there is an urgent need to develop therapies 
that target obesity in the pediatric and adolescent population. 
Unfortunately, lifestyle changes, including increased physical 
activity and dietary modification, achieve limited results (7), and 
pharmacologic therapy carries the risk of side effects without 
clear sustained benefit (8). Bariatric surgery is, thus, becoming 
an alternative for adolescents and young adults with moderate 
to severe obesity, particularly those with serious co-morbidities, 
in whom conservative therapy has proven ineffective. Studies 
have shown important short- and mid-term benefits of weight 
loss surgery in this population (9), and the American Society 
for Metabolic and Bariatric Surgery (ASMBS) has proposed that 
surgery should be offered relatively early to patients with severe 
obesity, rather than waiting until co-morbidities develop (10, 11).
Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy 
(SG) are the most commonly performed surgical weight loss pro-
cedures, and both are well tolerated and effective in adolescents 
with severe obesity (7, 12, 13). Although the choice of surgical 
procedure is often based on the patient’s characteristics and 
physician–patient discussion, data comparing outcomes from 
different bariatric procedures in the adolescent/young adult 
population would be useful to better guide surgical choice. A 
recent study evaluating long-term outcomes of RYGB vs. SG in 
adolescents showed significant weight reduction following both 
procedures as well as remission of T2D and dyslipidemia (14). 
However, impairment in liver function due to non-alcoholic fatty 
liver disease is also a potential consequence of obesity and it was 
not verified in the previous study. According to the ESPGHAN 
Hepatology Committee (15), patients with this condition may 
benefit from weight reduction following bariatric surgery. The 
current study aims to add to these data by comparing short-term 
outcomes at 1–6 months and longer-term outcomes 7–18 months 
following SG and RYGB performed at a single center with respect 
to changes in body mass index (BMI), metabolic and lipid profile, 
and liver enzymes in adolescents with severe obesity.
MaTerials anD MeThODs
We conducted a retrospective study with all adolescents, 
16–21 years old, who underwent RYGB or SG at our institution 
between January 2012 and December2014. All patients received 
pre-operative evaluation and care at the Weight Center of our 
institution. The choice for RYGB or SG was based on the patient’s 
preference after a detailed discussion of surgical procedures 
and outcomes with the surgeon. Data collected include demo-
graphics and pre- and post-operative measures of body weight 
and laboratory tests. Laboratory data include liver enzymes 
[alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST)], lipids [total cholesterol, triglycerides, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), 
and calculated non-HDL cholesterol], blood count (hematocrit, 
hemoglobin, and platelets), creatinine, and calcium metabolism 
parameters [calcium and 25-hydroxy vitamin D (25-OHD)]. In 
addition, information regarding a pre-existing diagnosis of T2D 
was extracted from medical charts. All patients had a liver biopsy 
at surgery in order to evaluate for non-alcoholic steatohepatitis 
(NASH). We considered a patient as having T2D if the patient 
had either a documented pre-operative diagnosis of T2D in the 
medical charts and either an HbA1c ≥6.5% (16, 17) or was using 
a hypoglycemic drug (with documented T2D before starting the 
hypoglycemic drug). Remission of T2D following surgery was 
defined as a decrease in HbA1c levels to below 6.0% and/or dis-
continuation of the hypoglycemic drug with subsequent normal 
fasting and/or random blood glucose. Information regarding 
duration of surgery, length of hospital stay, and occurrence of 
post-operative complications was collected.
Data collection was performed using the following criteria: (1) 
pre-operative laboratory assessments were obtained from a visit 
within 6 months before surgery. If more than one set of laboratory 
data was available, the set that was most comprehensive and/or 
closest to surgery was chosen. Baseline weight measurements 
were taken within 3  months preceding surgery. Adult height 
information was also collected. A patient was considered to have 
attained adult height if height measurements had plateaued on 
the patient’s growth chart and/or the chronological age at the 
time of height assessment was at least 15 years in a female and 
17 years in a male. This was based on Greulich and Pyle charts 
(18) that indicate that only 1% of growth persists at bone ages of 
15 and 17 in girls and boys, respectively. Of note, children with 
obesity typically have bone ages that exceed their chronological 
age (19). Thus, for children with obesity and chronological ages 
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of 15 in girls and 17 in boys, the bone age is likely even greater, 
indicating completion of statural growth. (2) Weight measure-
ments and laboratory values (i) 1–6 months and (ii) 7–18 months 
post-operatively were obtained from any clinic visit within the 
appropriate timeframe. If more than one set of data was available, 
the most comprehensive set and/or the set farthest from surgery 
was selected. Post-operative weight measurements were typically 
available at the time of blood draws. If not, they were obtained 
from any time point within a month of the blood draw.
All RYGB and SG procedures were performed laparoscopically 
using a similar technique for all patients undergoing the specific 
procedure. Eligibility was determined by Weight Center criteria, 
which for adolescents include a BMI ≥35 kg/m2 with severe co-
morbidities or BMI ≥40 kg/m2 with minor co-morbidities, com-
pletion of statural growth, demonstration of previous sustained 
efforts at non-surgical weight loss (lifestyle changes, including 
nutritional changes and physical activity), and determination by 
a physician, psychologist, and dietitian that sufficient maturity 
exists to recognize risks and benefits of the procedure and imple-
ment required post-operative behavioral changes (20). Patients 
were selected for RYGB or SG based on patient characteristics and 
the consensus of the Weight Center providers.
This study was approved by our Institutional Review Board, 
with a waiver of the requirement for informed consent based on 
the minimal risk for subjects and impracticability of obtaining 
consent for this retrospective review.
Sample size was based on expected BMI changes after surgery, 
and was determined based on variance data available from an 
earlier paper (SD of 3.5 kg/m2) (20). We expected that with 20 
patients in each of the surgical groups, the probability was 80% 
that the study would detect a BMI reduction of at least 3.5 kg/m2 
over time in each of the groups while keeping the false positive 
rate to less than 5%.
We used JMP (v10; SAS Institute, Inc., Cary, NC, USA) for 
all analyses. Data are reported as mean ± SD or median (IQR) 
(for between-group comparisons), mean difference ± SEM (for 
within-group changes over time), and 95% confidence intervals. 
Pre-operative baseline characteristics, and changes in BMI 
 measurements and laboratory values between the two surgery 
groups were analyzed using the Student t-test for normally 
 distributed data or the Wilcoxon rank-sum test for non-normally 
distributed variables. For the analysis comparing pre- and 
 post-operative measures within groups, we performed a paired 
t-test for normally distributed data and a Wilcoxon signed-rank 
test for data not normally distributed. Fisher’s exact test was used 
to compare proportions.
Follow-up information for BMI was available for the RYGB and 
SG groups at 1–6 months in all subjects and at 7–18 months in 83% 
of the RYGB and 64% of the SG subjects (p = 0.18). Laboratory 
information at 7–18 months was available in up to 67% of subjects 
in the RYGB group and 46% of those in the SG group (p = 0.23). 
The use of the paired t-test or Wilcoxon signed-rank test mitigates 
to some extent loss to follow-up as it takes into account only those 
individuals with data available at baseline (before surgery) and 
at follow-up. In addition, in our study, patients who were lost to 
follow-up did not differ from those who returned for follow-up 
at 7–18  months for (i) gender (2M/10F without follow-up vs. 
4M/30F with follow-up, p = 0.64), (ii) mean age (19.2 ± 1.7 with-
out follow-up vs. 18.8 ± 1.8 years old with follow-up, p = 0.51), 
(iii) race (0% Asian, 0% Black, 42% Hispanic, and 58% White 
without follow-up vs. 3% Asian, 9% Black, 33% Hispanic, and 
55% White with follow-up, p =  0.65), and (iv) BMI at surgery 
(50.6 ± 8.4 without follow-up vs. 49.8 ± 6.8kg/m2 with follow-up, 
p = 0.85). Median follow-up time did not differ between RYGB 
vs. SG groups [10.7 (7.8–11.8) months vs. 11.2 (8.7–14.6) months, 
p = 0.29].
resUlTs
Baseline characteristics
Forty-six patients underwent weight loss surgery between 
January 2012 and December 2014; 24 (52%) underwent RYGB 
and 22 (48%) SG. Of those, 25 patients (54%) were between 16 and 
18 years old [14 (56%) in RYGB and 11 (44%) SG groups, p = 0.77]. 
Baseline characteristics are shown in Table  1. Anthropometric 
measures and pre-operative laboratories were collected over an 
average period of 4.5 ± 3.9 months prior to surgery for RYGB and 
2.7 ± 3.0 months for SG groups with no significant differences 
between groups (p = 0.09). Groups did not differ for age, sex, race, 
pre-operative weight, or pre-operative BMI. For pre-operative 
laboratory measurements, patients in the SG group had higher 
creatinine than RYGB subjects, and patients in the RYGB group 
had higher LDL than the SG group. Other laboratory measures 
did not differ by surgery type.
changes in Weight and BMi
In the immediate post-operative period (1–6  months post-
operatively), BMI decreased significantly from baseline in both 
RYGB (−7.9 ±  0.7kg/m2, p <  0.0001) and SG (−7.5 ±  0.6  kg/
m2, p < 0.0001) groups compared to pre-operative values. These 
changes were not significantly different between groups (p = 0.65). 
As shown in Table 2 for outcomes assessed after 7–18 months of 
follow-up, there was again a marked reduction in BMI for both 
RYGB (−15.9 ± 1.1 kg/m2, p < 0.0001) and SG (−12.6 ± 1.7 kg/m2, 
p = 0.0002) groups, with a trend toward greater reductions in the 
RYGB group (p = 0.09). Percentage of excess BMI lost (%EBMIL) 
and percentage of total body weight loss did not differ between 
the RYGB and SG groups (Table 2). Only one patient had weight 
regain following SG (8.2 kg), while no patient regained weight 
after RYGB over an 18-month period. Weight regain was not seen 
in any subject at 1–6 months following surgery.
changes in Diabetes status
There were nine cases of pre-existing T2D, five in the RYGB group 
and four in the SG group. Overall, six patients had remission 
of T2D. Of the five pre-existing cases in the RYGB group, two 
patients had remission of T2D, one had normal HbA1c levels on 
a hypoglycemic drug, one had improvement in glucose levels but 
was not able to discontinue oral hypoglycemics, and the other was 
lost to follow-up. Of the four pre-existing cases in the SG group, 
three had initial remission of T2D, though one of these three 
patients had weight regain during follow-up with recurrence of 
diabetes. The fourth patient in the SG group had improvement in 
glucose levels but continued to need diabetes medication.
TaBle 1 | Baseline characteristics of groups undergoing sg vs. rYgB procedures.
rYgB surgery (n = 24) sg surgery (n = 22) p-Value
Age (years) 18.5 ± 1.7 (24) 19.4 ± 1.7 (22) 0.07
Sex (males/females) 1/23 5/17 0.09
Race/ethnicity (%) 0.71
Black 1 (4.2%) 2 (9.1%)
Hispanic 8 (33.3%) 8 (36.4%)
White 14 (58.3%) 12 (54.5%)
Asian 1 (4.2%) 0 (0)
Weight (kg) 137.2 ± 18.5 (24) 143.7 ± 30.4 (22) 0.72*
BMI (kg/m2) 50.3 ± 6.0 (24) 49.7 ± 8.4 (22) 0.79
Liver enzymes
Alkaline phosphatase (U/l) 78 ± 18 (20) 80 ± 24 (21) 0.94*
ALT (U/l) 30 ± 15 (22) 24 ± 16 (22) 0.09*
AST (U/l) 27 ± 12 (22) 22 ± 8 (22) 0.06*
Lipid profile
Triglycerides (mg/dl) 103 (84–119) (16) 104 (63–141) (10) 1.00*
Total cholesterol (mg/dl) 159 (134–135) (16) 146 (123–168) (10) 0.17
High-density lipoprotein (mg/dl) 39 (33–42) (16) 43 (38–49) (10) 0.18*
Low-density lipoprotein (mg/dl) 101 (79–118) (16) 74 (60–103) (10) 0.02
Non-HDL cholesterol (mg/dl) 117 (97–139) (16) 99 (82–123) (10) 0.06*
Blood count
Hematocrit (%) 40 ± 2.5 (18) 39 ± 3.7 (20) 0.22
Hemoglobin (g/dl) 13 ± 1.1 (18) 13 ± 1.2 (20) 0.22
Platelets (th/mm3) 311 ± 46 (21) 304 ± 64 (21) 0.67
Serum creatinine (mg/dl) 0.67 ± 0.09 (22) 0.74 ± 0.12 (22) 0.04
Calcium (mg/dl) 9.4 ± 0.36 (22) 9.4 ± 0.41 (21) 0.64
25(OH)D (ng/ml) 21 ± 7 (15) 23 ± 15 (12) 0.55
Type 2 diabetes (n = 9) 5 out of 24 4 out of 22 1.00
Non-alcoholic steatohepatitis (n = 14)a 8 out of 24 6 out of 22 0.75
Data are presented as mean ± SD or median (IQR). Sample sizes for each measure are shown in parentheses.
*The Wilcoxon rank-sum test was used to compare variables that were not normally distributed.
aNon-alcoholic steatohepatitis was diagnosed histologically by liver biopsy at the time of surgery.
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 25(OH)D, 25-hydroxyvitamin D.
Normative ranges: ALP (15–350 U/l), ALT (7–33 U/l), ASP (9–32 U/l), triglycerides (40–150 mg/dl), total cholesterol (<200 mg/dl), high-density lipoprotein (35–100 mg/dl), low-
density lipoprotein (<130 mg/dl), non-HDL cholesterol (<140 mg/dl), hematocrit (37–49%, males; 36–46%, females), hemoglobin (13–16 g/dl, males; 12–16 g/dl, females), platelets 
(150–450 th/mm3), calcium (8.5–10.5 mg/dl), 25(OH)D (33–96 ng/ml).
Bold indicates that values are statistically significant.
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changes in liver enzymes
The RYGB group had significantly greater reductions in ALT 
(p = 0.03) but not in AST levels 7–18 months post-operatively, 
whereas the SG group had a trend toward a reduction in ALT 
(p =  0.08) but not in AST over the follow-up period. NASH, 
diagnosed by liver biopsy at the time of surgery, was present in 
14 of 46 patients (8 in the RYGB and 6 in the SG groups). Subjects 
with evidence of NASH were classified according to NASH Stages 
(21). Forty-three percent (n = 6) had Stage I, 14% (n = 2) Stage 
II, and 14% (n = 2) Stage III NASH. No patient was diagnosed 
with Stage IV disease. Twenty-nine percent (n = 4) of patients 
with NASH had no fibrosis. When we divided patients into two 
categories according to NASH stages (Stages 0–I and II–III), we 
found that compared to patients with Stage 0–I NASH, those with 
Stage II–III NASH had greater baseline values for ALT (29 ± 8 
vs. 67 ± 25, p = 0.001) and AST (25 ± 13 vs. 47 ± 23, p = 0.046). 
At 1–6 months follow-up, patients with Stage II–III NASH had 
greater decreases in ALT (−45 ± 18 vs. −10 ± 3, p = 0.02) but not 
in AST (−19 ± 27 vs. −2 ± 2, p = 0.33) compared with patients 
with Stage 0−I NASH. Similarly, at 7−18  months follow-up, 
there were significant reductions in ALT (−45 ± 18 vs. −9 ± 3, 
p = 0.01) but not AST (2 ± 2 vs. −5 ± 2, p = 0.32) in those with 
Stage II−III NASH vs. those with Stage 0−I NASH. RYGB and SG 
groups did not differ for the magnitude of post-surgical changes 
in liver enzymes.
changes in lipids
Nine patients in the RYGB group and four patients in the SG group 
had dyslipidemia at baseline. This difference was not statistically 
significant between groups, p = 0.23. The RYGB group had sig-
nificant reductions in LDL (p = 0.003) and non-HDL cholesterol 
(p = 0.02), but not HDL cholesterol at 7–18 months follow-up 
(Table 2). The SG group did not have significant changes in the 
lipid profile, although there was a trend toward an increase in 
TaBle 2 | changes in BMi and biochemical parameters in rYgB and sg groups 7–18 months following surgery.
rYgB surgery sg surgery P (lsg vs. 
rYgB)
Pre-operative 7–18 months 
post-operative
Mean  
difference
Paired 
t-test
Pre-operative 7–18 months 
post-operative
Mean  
difference
Paired  
t-test
Mean ± sD Mean ± sD Mean ± seM P Mean ± sD Mean ± sD Mean ± seM P
BMI (kg/m2) 50.6 ± 6.5 (20) 34.7 ± 5.7 (20) −15.9 ± 1.1 <0.0001 48.7 ± 7.4 (14) 36.1 ± 11.3 (14) −12.6 ± 1.7 0.0002* 0.09
% Excess BMI lost – – −63.4 ± 4.7 – – – −58.4 ± 5.6 – 0.50
% Total body 
weight loss
– – −31.3 ± 2.2 – – – −26.8 ± 2.7 – 0.20
ALP (U/l) 81 ± 18 (14) 86 ± 28 (14) 5 ± 5 0.29 80.1 ± 29 (10) 73 ± 19 (10) −7 ± 7 0.31 0.13
ALT (U/l) 32 ± 16 (16) 23 ± 20 (16) −9 ± 5 0.03* 29 ± 22 (10) 17 ± 10 (10) −11 ± 7 0.08* 0.56*
AST (U/l) 28 ± 12 (16) 23 ± 14 (16) −5 ± 4 0.14* 24 ± 11 (10) 19 ± 5 (10) −6 ± 4 0.11* 0.87*
Triglycerides (mg/dl) 96 ± 18 (9) 101 ± 62 (9) 5 ± 21 0.68* 117 ± 40 (4) 90 ± 39 (4) −27 ± 16 0.18 0.40*
Total Cholesterol 
(mg/dl)
164 ± 21 (9) 148 ± 23 (9) −16 ± 5 0.02* 152 ± 24 (4) 150 ± 18 (4) −2 ± 8 0.77 0.19
HDL (mg/dl) 39 ± 3 (9) 46 ± 13 (9) 7 ± 4 0.10 43 ± 11 (4) 53 ± 13 (4) 10 ± 3 0.06 0.73
LDL (mg/dl) 106 ± 18 (9) 82 ± 15 (9) −24 ± 6 0.003 86 ± 25 (4) 79 ± 13 (4) −7 ± 9 0.50 0.12
Non-HDL (mg/dl) 125 ± 20 (9) 102 ± 27 (9) −23 ± 8 0.02* 109 ± 31 (4) 97 ± 19 (4) −12 ± 7 0.18 0.40
Hematocrit (%) 40.5 ± 2.8 (11) 38.8 ± 2.9 (11) −2 ± 1 0.14 39.9 ± 3.8 (10) 39.9 ± 3.9 (10) 0.0 ± 0.5 0.97 0.18
Hemoglobin (g/dl) 13.4 ± 1.3 (11) 12.7 ± 1.2 (11) −0.7 ± 0.4 0.10 13.1 ± 1.3 (10) 13.2 ± 1.3 (10) 0.1 ± 0.2 0.64 0.09
Platelets (th/mm3) 309 ± 51 (15) 267 ± 56 (15) −42 ± 15 0.01 283 ± 78 (10) 254 ± 55 (10) −30 ± 11 0.02 0.56
Creatinine (mg/dl) 0.7 ± 0.1 (16) 0.7 ± 0.1 (16) 0.0 ± 0.0 0.37* 0.7 ± 0.1 (10) 0.7 ± 0.1 (10) 0.0 ± 0.0 0.02 0.67
Calcium (mg/dl) 9.5 ± 0.4 (16) 9.5 ± 0.4 (16) 0.0 ± 0.1 0.67 9.4 ± 0.5 (10) 9.5 ± 0.5 (10) 0.1 ± 0.1 0.51 0.81
25(OH)D (ng/ml) 21 ± 8 (9) 30 ± 13 (9) 9 ± 5 0.13 27 ± 19 (7) 35 ± 18 (7) 8 ± 5 0.16 0.92*
Sample size for each measure is shown in parentheses.
*Wilcoxon signed-rank test was used for non-normally distributed data.
BMI, body mass index; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein cholesterol; LDL, low-density 
lipoprotein cholesterol; 25(OH)D, 25-hydroxyvitamin D.
Normative ranges: ALP (15–350 U/l), ALT (7–33 U/l), ASP (9–32 U/l), triglycerides (40–150 mg/dl), total cholesterol (<200 mg/dl), HDL (35–100 mg/dl), LDL (<130 mg/dl), non-HDL 
(<140 mg/dl), hematocrit (37–49%, males; 36–46%, females), hemoglobin (13–16 g/dl, males; 12–16 g/dl, females), platelets (150–450 th/mm3), calcium (8.5–10.5 mg/dl), 25(OH)D 
(33–96 ng/ml).
Bold indicates that values are statistically significant.
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HDL cholesterol (p  =  0.06). Between-group comparisons of 
changes in lipids over 7–18 months did not show significant dif-
ferences, even after controlling for baseline values.
changes in Blood count Parameters
Changes in hematocrit and hemoglobin levels over the follow-up 
period did not differ either within groups or between groups 
undergoing RYGB or SG (Table 2). Platelets decreased in both 
RYGB and SG groups (p = 0.01 and 0.02, respectively) (Table 2).
changes in calcium Metabolism
Calcium and 25(OH) D levels did not change in either group over 
7–18 months. Groups did not differ for prevalence of vitamin D 
deficiency either before or after surgery (data not shown).
surgical Time and Post-Operative 
complications
Mean surgical time for RYGB vs. SG, respectively, was 3.1 ± 0.3 
vs. 2.6 ± 0.5 h (p = 0.001), and mean length of hospital stay was 
2.2 ± 0.4 vs.1.9 ± 0.3 days (p = 0.01). Post-operative complica-
tions occurred in one patient following RYGB (post-prandial 
vomiting) and no patient following SG (p = 0.33).
DiscUssiOn
Few data are currently available comparing outcomes of differ-
ent bariatric surgery techniques in the adolescents. Our data 
demonstrate 1–6  months and 7–18  months reductions in BMI 
following both RYGB and SG, and no difference between the 
groups for changes in BMI and weight regain following surgery, 
indicating that both RYGB and SG are effective options for weight 
loss in adolescents. This is consistent with prior studies by Inge 
et al. (14) and Cozacov et al. (22). However, weight reduction at 
7–18 months following RYGB trended higher than that follow-
ing SG. Although surgical time and length of stay at the hospital 
were greater in the RYGB group, the rate of post-operative com-
plications did not significantly differ between groups. This is in 
accordance with prior studies (23) and supports the safety profile 
of both procedures.
Thirty percent of patients had findings consistent with NASH 
on liver biopsy performed at the time of surgery. Following surgery, 
transaminases improved in both groups, suggesting improve-
ment in fatty liver disease, although this was not verified by repeat 
biopsy. A decrease in ALT occurred following both RYGB and 
SG. When considering patients who had a diagnosis of NASH 
at the time of surgery, patients presenting with Stages II–III had 
greater improvement in their liver enzymes when comparing to 
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those classified as Stages 0–I. This is consistent with our previous 
study, which showed a decrease in AST and ALT following RYGB 
in a subgroup of patients who had elevated baseline liver func-
tion tests, but not in the whole group of patients (20). Moreover, 
Xanthakos et al. (24) found a positive association between higher 
ALT levels and chances of more severe non-alcoholic fatty liver 
disease. To our knowledge, data are not available regarding 
changes in AST/ALT following SG in adolescents, and our study 
indicates no differences between RYGB vs. SG groups for changes 
in liver enzymes.
With regard to metabolic parameters, lipid levels improved 
following both RYGB and SG. Seven to 18  months changes in 
LDL appeared to be of greater magnitude in the RYGB group. 
These findings suggest that RYGB may prove to be more ben-
eficial for LDL improvement when compared to SG and may be 
favored in those with severe dyslipidemia. However, baseline LDL 
values were higher in the RYGB group, and we cannot exclude 
regression to the mean as an explanation for this finding. The 
improvement in lipid levels seen in our study is consistent with 
previous literature (7, 13, 14, 20). However, changes in lipid values 
were at the normal range and the clinical impact of these is still 
poorly understood. Further evaluation of the long-term impact of 
RYGB on lipids and cardiovascular disease outcomes is needed.
Anemia has been reported in 25–50% of the patients follow-
ing RYGB (25, 26). Iron deficiency anemia is the most common 
cause and it may take years to develop. In our study, anemia 
was not observed during the 7–18 months follow-up period in 
either of the groups. This may be a reflection of a relative short 
follow-up period and/or an increased intake of supplements 
post-operatively.
Although vitamin D deficiency is common following bariatric 
surgery (27) and reported in 50–80% patients after RYGB (28), 
our study demonstrated no decrease in vitamin D levels for 
either surgical group over 7–18 months of follow-up. This may 
be a reflection of increased supplement intake after surgery and/
or a high prevalence of vitamin D insufficiency prior to surgery. 
Vitamin D regulates calcium metabolism through its impact 
on PTH secretion, and our patients demonstrated normal PTH 
levels at 7–18 months follow-up with no difference across groups.
Our study has some limitations. First, this is a retrospective 
study and uses clinical data that were not uniformly collected in all 
subjects. It is possible that subjects with more favorable outcomes 
are more likely to present for clinical follow-up, whereas those 
without favorable outcomes are less likely to return for follow-up. 
However, it is also possible that those with the best outcome no 
longer see a reason to follow up and are the ones that are lost 
follow-up. A second limitation is that patients who underwent 
RYGB and SG were not matched for some baseline measures, such 
as creatinine and LDL, which may have influenced some results 
of comparisons of post-surgical changes. In addition, we have a 
relatively small sample size and a limited time frame for evalua-
tion of post-operative changes. Longer studies with larger sample 
sizes will be needed to confirm the present findings. Finally, we 
did not have sufficient post-operative fasting glucose and insulin 
values available to report quantitative changes in glucose metabo-
lism. However, in evaluating patients with pre-existing diabetes, 
we found that at least 67% of subjects had achieved remission 
and 22% had improved glycemic levels following surgery. This 
is consistent with previous studies showing remission of T2D 
following bariatric procedures (7, 12–14, 20, 22).
In spite of its limitations, the current study adds to the litera-
ture, as there are limited data regarding outcomes of bariatric sur-
gery in adolescents and young adults and there is only one larger 
study comparing outcomes of RYGB vs. SG in this population 
(14). However, the prior study did not report effects of surgery on 
liver enzymes. Consistent with this prior study, we demonstrate 
no difference in changes in BMI when comparing procedures. 
Further studies are also necessary to better understand differ-
ences in laboratory outcomes and resolution of co-morbidities 
between the two procedures.
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